{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:16Z","timestamp":1740106936130,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00277-020-04143-x","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T22:02:31Z","timestamp":1592431351000},"page":"2191-2192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Marko","family":"Lucijanic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-285X","authenticated-orcid":false,"given":"Ozren","family":"Jaksic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"4143_CR1","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/bjh.16563","volume":"189","author":"F D\u2019Al\u00f2","year":"2020","unstructured":"D\u2019Al\u00f2 F, Malafronte R, Piludu F, Bellesi S, Cuccaro A, Maiolo E, Modoni A, Leccisotti L, Macis G, Mores N, De Stefano V, Hohaus S (2020) Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance. Br J Haematol 189:e140\u2013e144. https:\/\/doi.org\/10.1111\/bjh.16563","journal-title":"Br J Haematol"},{"issue":"6","key":"4143_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00277-002-0458-3","volume":"81","author":"O Hequet","year":"2002","unstructured":"Hequet O, Salles G, Espinousse D, Dumontet C, Bouafia F, Thieblemont C, Revesz D, Coiffier B (2002) Multifocal progressive leukoencephalopathy occurring after refractory anemia and multiple infectious disorders consecutive to severe lymphopenia. Ann Hematol 81(6):340\u2013342. https:\/\/doi.org\/10.1007\/s00277-002-0458-3","journal-title":"Ann Hematol"},{"issue":"2","key":"4143_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00277-008-0567-8","volume":"88","author":"C Visco","year":"2009","unstructured":"Visco C, Marchioni E, Pomponi F, Ferrante P, Delbue S, Pellizzer G, Rodeghiero F (2009) Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination? Ann Hematol 88(2):189\u2013191. https:\/\/doi.org\/10.1007\/s00277-008-0567-8","journal-title":"Ann Hematol"},{"issue":"6","key":"4143_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00277-018-3552-x","volume":"98","author":"V Pejsa","year":"2019","unstructured":"Pejsa V, Lucijanic M, Jonjic Z, Prka Z, Vukorepa G (2019) Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia. Ann Hematol 98(6):1509\u20131510. https:\/\/doi.org\/10.1007\/s00277-018-3552-x","journal-title":"Ann Hematol"},{"issue":"2","key":"4143_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12185-012-1118-6","volume":"96","author":"S Warsch","year":"2012","unstructured":"Warsch S, Hosein PJ, Morris MI, Teomete U, Benveniste R, Chapman JR, Lossos IS (2012) Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. Int J Hematol 96(2):274\u2013278. https:\/\/doi.org\/10.1007\/s12185-012-1118-6","journal-title":"Int J Hematol"},{"key":"4143_CR6","doi-asserted-by":"publisher","first-page":"534529","DOI":"10.1155\/2015\/534529","volume":"2015","author":"KA Silverio","year":"2015","unstructured":"Silverio KA, Patel SA (2015) Progressive multifocal leukoencephalopathy with negative JC virus PCR following treatment of follicular lymphoma: implications for biologics in the era of targeted cancer therapy. Case Rep Oncol Med 2015:534529\u2013534526. https:\/\/doi.org\/10.1155\/2015\/534529","journal-title":"Case Rep Oncol Med"},{"issue":"23","key":"4143_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","volume":"77","author":"J Kuhle","year":"2011","unstructured":"Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkewitsch C, Major EO, Kappos L, Frank S, Hirsch HH (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77(23):2010\u20132016. https:\/\/doi.org\/10.1212\/WNL.0b013e31823b9b27","journal-title":"Neurology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04143-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04143-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04143-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T23:49:24Z","timestamp":1623887364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04143-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4143"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04143-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ML received speaker honoraria from Roche and Sandoz, and OJ received speaker honoraria from Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Patient\u2019s family provided informed consent for publishing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}